Further support for alpelisib’s biological activity was provided by a phase II study of alpelisib monotherapy, which demonstrated that early reductions in PIK3CA mutations detected in circulating tumor DNA (ctDNA) were strongly associated with improved outcomes. The gene discussed is PIK3CA; the disease is neoplasm.